Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
Links shared publicly online about this topic.
- 1,503total visits
Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
Actelion Ltd (SIX: ATLN) announced today that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant comp
View full resource at medicalnewstoday.com
Tags: Sleep Disorder, Insomnia
Most Recently Shared on December 26, 2009 at 11:06 am By:
Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Prima... http://mnt.to/3vKf
Also Shared By:
Advertisement
MNT Clinical Trials
@mnt_clinical
Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Prima... http://mnt.to/3vKf
1 year ago...